Dan is a managing director at Access Biotechnology, where he leads investments in transformative therapies for conditions with high unmet needs and that have the potential to meaningfully impact human health. He serves on the boards of Day One Biopharmaceuticals (NASDAQ: DAWN), Acelyrin (NASDAQ: SLRN), and multiple private companies, and previously served on the boards of Pandion Therapeutics (NASDAQ: PAND) until its acquisition by Merck, Principia Biopharma (NASDAQ: PRNB) until its acquisition by Sanofi, and DTx Pharma until its acquisition by Novartis. Prior to Access Biotechnology, Dan was a principal at New Leaf Venture Partners, where he played a key role in multiple private and public biopharma investments. Before that, Dan was a principal in the Health Care practice at the Boston Consulting Group, where he led projects across the health care sector with an emphasis on biopharma R&D. Dan trained clinically in internal medicine and nephrology at Brigham and Women’s Hospital and Massachusetts General Hospital, and was a Research Fellow at Harvard Medical School. He obtained both his M.D. and Ph.D. in cellular and molecular biology from the University of Michigan and received his B.S. in physiology from the University of Illinois at Urbana-Champaign.